Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.68 |
| ▸ | MAPK13 | O15264 | 12/20 | 0.68 |
| ▸ | MAPK12 | P53778 | 11/20 | 0.68 |
| ▸ | MAPK11 | Q15759 | 11/20 | 0.68 |
| ▸ | CDK8 | P49336 | 2/20 | 0.65 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.58 |
| ▸ | JAK2 | O60674 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | CCNC | P24863 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1599571 | 0.94 | CDK8 (0.69) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL1012616 | 0.94 | MAPK13 (0.66) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL15492491 | 0.92 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL15469397 | 0.92 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL1013690 | 0.92 | MAPK13 (0.59) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL1013743 | 0.91 | MAPK14 (0.73) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL1013230 | 0.91 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL1012997 | 0.91 | MAPK14 (0.66) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| SCHEMBL1793950 | 0.91 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11CDK8 | |
| Carbamic Acid SCHEMBL1780358 | 0.91 | MAPK13 (0.62) | MAPK14MAPK13MAPK12MAPK11CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819998-B1 | CRYSTALLINE FORMS OF 1-(3-TERT-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETHYL)-1H-INDAZOL-5-YLOXY)BENZYL)UREA HYDROCHLORIDE | ARRAY BIOPHARMA INC (US) | 2022-04-06 | — | — | EP | claimed |
| US-9278936-B2 | Crystalline forms of 1-(3-tert-butyl-1-p-tolyl-1H-pyrazol-5-yl)-3-(5-fluoro-2-(1-(2-hydroxyethyl)-1H-indazol-5-yloxy)benzyl)urea hydrochloride | ARRAY BIOPHARMA INC. (US) | 2016-03-08 | — | — | US | claimed |
| US-20150030673-A1 | CRYSTALLINE FORMS OF 1-(3-TERT-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETHYL)-INDAZOL-5-YLOXY)BENZYL)UREA HYDROCHLORIDE | ARRAY BIOPHARMA INC. (US) | 2015-01-29 | — | — | US | claimed |
| EP-2819998-A1 | CRYSTALLINE FORMS OF 1- (3 -TERT-BUTYL- 1 - P-TOLYL- 1H- PYRAZOL- 5 -YL) -3- (5-FLUORO-2- (1- ( 2 - HYDROXYETHYL) - INDAZOL- 5 -YLOXY) BENZYL) UREA HYDROCHLORIDE | Array Biopharma, Inc. (US) | 2015-01-07 | — | — | EP | claimed |
| WO-2013130573-A1 | CRYSTALLINE FORMS OF 1- (3 -TERT-BUTYL- 1 - P-TOLYL- 1H- PYRAZOL- 5 -YL) -3- (5-FLUORO-2- (1- ( 2 - HYDROXYETHYL) - INDAZOL- 5 -YLOXY) BENZYL) UREA HYDROCHLORIDE | ARRAY BIOPHARMA INC. (US) | 2013-09-06 | — | — | WO | claimed |
| CN-113264921-B | Pyrazolyl-ureas as kinase inhibitors | 瑞斯比维特有限公司 | 2024-09-13 | — | — | CN | disclosed |
| US-12006337-B2 | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof | WASHINGTON UNIVERSITY (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-4219489-A2 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Washington University (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-4219489-A2 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | Washington University (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 2023-06-22 | — | — | US | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-12-13 | — | — | US | disclosed |
| WO-2007125330-A1 | IMIDAZO[4, 5-B]PYRIDIN-2-ONE AND OXAZOLO[4, 5-B]PYRIDIN-2-ONE COMPOUNDS AND ANALOGS THEREOF AS CANCER THERAPEUTIC COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007089646-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007089646-A1 | KINASE INHIBITORS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2007-08-09 | — | — | WO | disclosed |
| US-6825184-B2 | FOR USE AS ANTI-INFLAMMATORY AGENTS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2004-11-30 | — | — | US | disclosed |
| US-20030162968-A1 | 1,4-Disubstituted benzo-fused urea compounds | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006337-B2 | Mitogen-activated protein kinase inhibitors, methods of making, and methods of use thereof | MAPK13, MAPK12, MAP3K13 | MAPK14 4/4885MAPK13 1/4885MAPK12 2/4885 |
| US-20230192728-A1 | MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS, METHODS OF MAKING, AND METHODS OF USE THEREOF | MAPK13, MAPK12, MAP3K13 | MAPK14 4/4885MAPK13 1/4885MAPK12 2/4885 |
| US-20030162968-A1 | 1,4-Disubstituted benzo-fused urea compounds | NFKBIA, MPO, RELA | MAPK14 3603/4885MAPK13 4000/4885MAPK12 3754/4885 |
| US-20150030673-A1 | CRYSTALLINE FORMS OF 1-(3-TERT-BUTYL-1-P-TOLYL-1H-PYRAZOL-5-YL)-3-(5-FLUORO-2-(1-(2-HYDROXYETHYL)-INDAZOL-5-YLOXY)BENZYL)UREA HYDROCHLORIDE | TTR, HK1, REN | MAPK14 2972/4885MAPK13 2869/4885MAPK12 3988/4885 |
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | MAPK14 694/4885MAPK13 670/4885MAPK12 1037/4885 |
| US-20070287838-A1 | Imidazo[4,5-B]Pyridin-2-One and Oxazolo[4,5-B]Pyridin-2-One Compounds and Analogs Thereof as Therapeutic Compounds | NR2E1, NR0B1, BRAF | MAPK14 722/4885MAPK13 339/4885MAPK12 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.